Israel Seed Iv L P Who Is Finjan Holdings, Inc. (FNJN) Insider, Sold 71,820 Shares of the Company; 2 Analysts Covering United Therapeutics (UTHR)

Among 12 analysts covering United Therapeutics (NASDAQ:UTHR), 2 have Buy rating, 4 Sell and 6 Hold. Therefore 17% are positive. United Therapeutics had 28 analyst reports since July 29, 2015 according to SRatingsIntel. Cowen & Co maintained it with “Outperform” rating and $185 target in Monday, August 17 report. The stock has “Hold” rating by Argus Research on Tuesday, May 24. H.C. Wainwright maintained United Therapeutics Corporation (NASDAQ:UTHR) on Thursday, October 26 with “Hold” rating. The stock of United Therapeutics Corporation (NASDAQ:UTHR) has “Underweight” rating given on Tuesday, November 29 by Barclays Capital. On Thursday, December 15 the stock rating was initiated by Oppenheimer with “Outperform”. The stock has “Buy” rating by Ladenburg Thalmann on Friday, October 28. As per Thursday, September 14, the company rating was maintained by Jefferies. As per Friday, February 26, the company rating was maintained by Barclays Capital. The rating was downgraded by Standpoint Research on Thursday, January 19 to “Hold”. On Wednesday, December 27 the stock rating was maintained by Wedbush with “Buy”. See United Therapeutics Corporation (NASDAQ:UTHR) latest ratings:

19/01/2018 Broker: Barclays Capital Rating: Sell New Target: $115.0
04/01/2018 Broker: Wedbush Rating: Buy New Target: $232.0 Maintain
27/12/2017 Broker: Wedbush Rating: Buy New Target: $232.0 Maintain
13/11/2017 Broker: Wedbush Rating: Buy New Target: $213.0 Maintain
26/10/2017 Broker: Cowen & Co Rating: Hold New Target: $129.0 Maintain
26/10/2017 Broker: H.C. Wainwright Rating: Hold New Target: $95.0 Maintain
14/09/2017 Broker: Jefferies Rating: Sell New Target: $105.0 Maintain
13/08/2017 Broker: Jefferies Rating: Sell New Target: $105.0000 Maintain
30/07/2017 Broker: Oppenheimer Rating: Buy New Target: $175.0000 Maintain
28/07/2017 Broker: H.C. Wainwright Rating: Hold New Target: $95.0000 Maintain

The insider of Finjan Holdings Inc, Israel Seed Iv L P, has just sold – 71,820 shares of the firm – coming to an aggregate transaction of $167,879 U.S Dollars (this based on avg share price of $2.3). Israel Seed Iv L P now owns 10%+ of the stock market cap of the company. More details about the deal dated 24-01-2018, could be found on hand in a legally required report on the SEC website here.

The stock decreased 4.88% or $0.1099 during the last trading session, reaching $2.1401. About 263,457 shares traded. Finjan Holdings, Inc. (NASDAQ:FNJN) has risen 114.51% since January 24, 2017 and is uptrending. It has outperformed by 97.81% the S&P500.

Finjan Holdings, Inc., through its subsidiaries, operates as a cybersecurity company, provides intellectual property licensing and enforcement services. The company has market cap of $59.30 million. The firm owns a portfolio of patents related to software and hardware technologies that proactively detect malicious code and thereby protects end users from identity and data theft, spyware, malware, phishing, trojans, and other Web and network threats. It has a 6.19 P/E ratio. The Company’s patented technologies are used in specific cybersecurity technology areas, including endpoint/cloud software, Web gateway/Internet infrastructure, networking equipment markets, and mobile security.

Analysts await Finjan Holdings, Inc. (NASDAQ:FNJN) to report earnings on March, 26. They expect $-0.04 earnings per share, down 123.53% or $0.21 from last year’s $0.17 per share. After $-0.16 actual earnings per share reported by Finjan Holdings, Inc. for the previous quarter, Wall Street now forecasts -75.00% EPS growth.

Among 2 analysts covering Finjan Holdings (NASDAQ:FNJN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Finjan Holdings has $5.0 highest and $4.0 lowest target. $5’s average target is 133.63% above currents $2.1401 stock price. Finjan Holdings had 3 analyst reports since May 20, 2016 according to SRatingsIntel. B. Riley & Co initiated the stock with “Buy” rating in Friday, May 20 report. As per Tuesday, January 2, the company rating was maintained by FBR Capital.

United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company has market cap of $6.02 billion. The companyÂ’s product candidates include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, a once-daily PDE-5 inhibitor to enhance the exercise ability in PAH patients. It has a 12.36 P/E ratio. It also provides Unituxin for the treatment of pediatric patients with high-risk neuroblastoma who achieve a partial response to prior first-line multiagent multimodality therapy.

Since August 3, 2017, it had 0 insider buys, and 15 sales for $2.30 million activity. ROTHBLATT MARTINE A sold $147,868 worth of United Therapeutics Corporation (NASDAQ:UTHR) on Thursday, September 21. Shares for $77,998 were sold by CAUSEY CHRISTOPHER.

The stock decreased 2.47% or $3.52 during the last trading session, reaching $139.2. About 156,921 shares traded. United Therapeutics Corporation (NASDAQ:UTHR) has risen 9.78% since January 24, 2017 and is uptrending. It has underperformed by 6.92% the S&P500.